ResMed (RMD) has been performing robustly with strong revenue and profit growth. Amidst volatility, it has demonstrated consistent growth, specifically over the last five years which would have delivered substantial gains to investors. Showing market leadership, ResMed continues to innovate with the launch of its NightOwl device aimed at simplifying home sleep apnea testing across the US. Its recent earnings have surpassed estimates, advocating solid financial performance. ResMed's transformative approach to the sleep health market positions it favorably in the long term. Moreover, the strength has been acknowledged by renowned market analysts including Jim Cramer, who conveyed his bullish sentiments on ResMed. However, there have been areas of concern such as insider share sales and the negative impact of potential competition from Eli Lilly's obesity drug. Although ResMed's stock has shown some weakness lately, the company's financials remain strong. ResMed is also set to report its Q3 fiscal 2025 earnings on April 23, 2025 with a positive outlook.
Resmed RMD News Analytics from Mon, 24 Jun 2024 07:00:00 GMT to Sat, 12 Apr 2025 06:49:59 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -1
